secwatch.observer — SEC 8-K summary
======================================

Issuer:     Personalis, Inc. (PSNL)
CIK:        0001527753
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0000950170-24-055585
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Personalis Q1 revenue $19.5M beats guidance; raises FY24 revenue outlook to $76-78M
--------------------------------------------------------------------------------

- Q1 2024 revenue $19.5M (up 3% YoY), exceeding upper-end of guidance; pharma testing revenue grew 55% to $9.8M.
- Net loss narrowed to $13.0M from $28.7M in Q1 2023, aided by $4.8M non-cash gain on Tempus warrants.
- Raised FY2024 total revenue guidance to $76-78M from $73-75M; non-GAAP net loss improved to ~$77M from prior ~$80M.
- Cash and short-term investments $95.4M; Q2 2024 revenue expected $19.5-20.5M.
- NeXT Personal MRD test published in Oncotarget; 338 molecular tests delivered; five ASCO abstracts accepted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527753/000095017024055585/0000950170-24-055585-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527753/000095017024055585/psnl-20240508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-055585

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer